Abstract

Amyotrophic lateral sclerosis, a devastating neurodegenerative disease, is characterized by the progressive loss of motor neurons and the accumulation of misfolded protein aggregates. The latter suggests impaired proteostasis may be a key factor in disease pathogenesis, though the underlying mechanisms leading to the accumulation of aggregates is unclear. Further, recent studies have indicated that motor neuron cell death may be mediated by astrocytes. Herein we demonstrate that ALS patient iPSC-derived astrocytes modulate the autophagy pathway in a non-cell autonomous manner. We demonstrate cells treated with patient derived astrocyte conditioned medium demonstrate decreased expression of LC3-II, a key adapter protein required for the selective degradation of p62 and ubiquitinated proteins targeted for degradation. We observed an increased accumulation of p62 in cells treated with patient conditioned medium, with a concomitant increase in the expression of SOD1, a protein associated with the development of ALS. Activation of autophagic mechanisms with Rapamycin reduces the accumulation of p62 puncta in cells treated with patient conditioned medium. These data suggest that patient astrocytes may modulate motor neuron cell death by impairing autophagic mechanisms, and the autophagy pathway may be a useful target in the development of novel therapeutics.

Highlights

  • Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disease, is characterized by the progressive loss of motor neurons

  • Cells were first characterized as pluripotent by demonstrating strong staining of Alkaline Phosphatase (AP), with high expression observed at the perimeter of the expanding induced pluripotent stem cells (iPSCs) colonies (Fig. 1a)

  • To further investigate the pathologic mechanisms associated with ALS patient astrocyte conditioned medium (ACM), we investigated the expression of ALS-related proteins SOD1 and TDP-43, two of the most common proteins associated with the pathogenesis of ALS (Fig. 5)

Read more

Summary

Introduction

Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disease, is characterized by the progressive loss of motor neurons. Death typically occurs within 2–5 years of onset, usually due to respiratory failure [1] and currently there is no efficacious therapy available [2]. ALS is associated with mutations in a wide number of genes, with C9ORF72 and SOD1 mutations being the most common [3]. The mechanisms by which these mutations cause ALS remain elusive. ALS is a heterogeneous condition, and defects in several molecular pathways have been identified, including oxidative stress [4], impaired axonal transport [5], glutamate excitotoxicity [6] and the secretion of toxic factors by non-neuronal cells [7].

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.